Samoco Begins Prototyping Flagship Product with PHTA Makerspace

Key Takeaways

• Samoco prototypes blood transport device in PHTA Makerspace
• Device cools and agitates blood for drone delivery
• Targets trauma deaths in low‑income regions
• First commercial user of PHTA Makerspace
• Potential civilian and military applications worldwide

Summary

Samoco, a smart medical transport device firm, has begun prototyping its flagship blood‑preservation system in the PHTA Makerspace. The device actively cools and agitates blood during road or drone transport, aiming to keep units viable in hot, remote environments. Up to 60 % of trauma deaths in low‑ and middle‑income countries are linked to blood loss, a problem the technology seeks to mitigate. The partnership leverages PHTA’s rapid‑fabrication resources, marking Samoco as the first commercial user of the new innovation hub.

Pulse Analysis

The shortage of refrigerated transport for blood products remains a critical bottleneck in low‑ and middle‑income countries, where up to 60 % of trauma deaths stem from uncontrolled hemorrhage. Conventional logistics struggle with long distances, high ambient temperatures, and the risk of bacterial proliferation, often rendering donated units unusable before they reach patients. Emerging drone networks promise faster point‑of‑need delivery, yet without a means to maintain optimal temperature and prevent cell degradation, the technology cannot fulfill its life‑saving potential. Addressing this gap is essential for improving emergency care in remote settings.

Samoco’s flagship device tackles the problem by continuously agitating and cooling blood throughout transport, whether by road or unmanned aerial vehicle. The company has moved from computer‑aided design to a physical prototype inside the PHTA Makerspace, leveraging the hub’s 4,000‑sq‑ft rapid‑fabrication facilities and specialist engineering support. This collaboration accelerates iteration cycles, reduces development costs, and validates performance under realistic temperature and vibration conditions. By being the first commercial user of the Makerspace, Samoco demonstrates how university‑linked innovation ecosystems can de‑risk medical‑device projects and bring solutions to market faster.

The implications extend beyond humanitarian aid. A reliable, temperature‑controlled blood transport system opens new markets for civilian emergency services, disaster response, and military field hospitals that require on‑the‑move transfusion capabilities. Investors are increasingly eyeing health‑tech ventures that combine IoT monitoring, cold‑chain logistics, and autonomous delivery, positioning Samoco for strategic partnerships and scaling opportunities. Moreover, the success of this prototype underscores the value of public‑private research facilities like PHTA, which nurture early‑stage companies and catalyze breakthroughs that can reshape global health infrastructure.